Comprehensive Solutions for Your Biotherapeutic and Vaccine Programs
At Emergent, our drug substance development teams are ready to work closely with you to deliver a solution honed to your specific needs. We help biopharma organizations in all program phases successfully manage the development and scale-up of cGMP-compliant drug substance processes.
With more than 20 years of process development experience, Emergent CDMO provides its clients with distinct advantages for their biological programs:
- Proteins (recombinant, plasma, fusion)
- Antibodies (mAbs, antibody fragments)
- Nanoparticle platforms